Drugs / Acelarin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02351765 | Jan 2016 → Mar 2019 | ampulla of vater cancer, cholangiocarcinoma, gallbladder cancer | The Christie NHS Foundation Trust | Completed | No outcome recorded |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT03610100 | Dec 2015 → Sep 2020 | pancreatic acinar cell carcinoma | The Clatterbridge Cancer Centre NHS Foundation Trust | Suspended | Missed primary Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Acelarin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03610100 ↗ |
| Modality | Other / unclassified | “first-in-class nucleotide analogue” NCT03610100 ↗ |
| Route | Intravenous | “administered intravenously” NCT03610100 ↗ |